Use of cigarettes, alcohol, and abuse of prescription pain relievers among teens has declined since 2013 while marijuana use rates…
Author National Institute on Drug Abuse
Details of the role of glutamate, the brain’s excitatory chemical, in a drug reward pathway have been identified for the…
A moderate dose of MDMA, commonly known as Ecstasy or Molly, that is typically nonfatal in cool, quiet environments can be…
People with severe mental illness such as schizophrenia or bipolar disorder have a higher risk for substance use, especially cigarette smoking, and protective factors usually associated with lower rates of substance use do not exist in severe mental illness, according to a new study funded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health.
A study using mice provides insight into how a specific receptor subtype in the brain could play a role in increasing a person’s risk for attention-deficit hyperactivity disorder (ADHD). The research, conducted by the Intramural Research Program (IRP) at the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, could also help explain how stimulants work to treat symptoms of ADHD.
An analysis of national prescribing patterns shows that more than half of patients who received an opioid prescription in 2009 had filled another opioid prescription within the previous 30 days. This report also suggested potential opportunities for intervention aimed at reducing abuse of prescription opioids.
Fueled by increases in marijuana use, the rate of eighth-graders saying they have used an illicit drug in the past year jumped to 16 percent, up from last year’s 14.5 percent, with daily marijuana use up in all grades surveyed, according to the 2010 Monitoring the Future Survey (MTF).
A regulatory protein best known for its role in a rare genetic brain disorder also may play a critical role in cocaine addiction, according to a recent study in rats, funded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health. The study was published today in the journal Nature Neuroscience.
Normal individuals who scored high on a measure of impulsive/antisocial traits display a hypersensitive brain reward system, according to a brain imaging study by researchers at Vanderbilt University. The findings provide the first evidence of differences in the brain’s reward system that may underlie vulnerability to what’s typically referred to as psychopathy.
Nicotine withdrawal is a major reason why smokers have trouble quitting. While it is well-known that nicotine exerts its rewarding effects by attaching to nicotine receptors in the brain, the mechanisms underlying nicotine withdrawal remain poorly understood.
Children of drug abusers are at high risk for a wide-range of negative outcomes, including developmental and cognitive disabilities and substance abuse disorders.
Addiction and bipolar disorder are commonly co-occurring disorders, with up to 60% of individuals with bipolar disorder experiencing some form of substance abuse in their lifetime. While it is known that genetic factors contribute substantially to the likelihood of developing either illness, new studies suggest shared genetic roots for both disorders.
Some of the same brain mechanisms that fuel drug addiction in humans accompany the emergence of compulsive eating behaviors and the development of obesity in animals, according to research funded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health.
Researchers have identified a key epigenetic mechanism in the brain that helps explain cocaine’s addictiveness, according to research funded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health.
Immunization with an experimental anti-cocaine vaccine resulted in a substantial reduction in cocaine use in 38 percent of vaccinated patients in a clinical trial supported by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health. The study, published in the October issue of Archives of General Psychiatry, is the first successful, placebo-controlled demonstration of a vaccine against an illicit drug of abuse.